6835-50-3

Upstream product

• 821-41-0 5-Hexen-1-ol 
• 122-04-3 4-nitro-benzoyl chloride 
• 62-23-7 4-nitro-benzoic acid 

Downstream Products

• 861405-34-7 (5R)-5,6-dihydroxyhexyl 4-nitrobenzoate 
• 917509-94-5 hex-5-enyl 4-aminobenzoate 
• 13476-55-6 hexyl 4-aminobenzoate 
• 861405-32-5 5,6-bis(nitrooxy)hexyl 4-nitrobenzoate 
• 861405-26-7 (5R)-5,6-bis(nitrooxy)hexyl 4-nitrobenzoate 
• 861405-27-8 (5S)-5,6-bis(nitrooxy)hexyl 4-nitrobenzoate 
• 1262956-66-0 (5S)-5,6-dihydroxyhexyl 4-nitrobenzoate 

Relevant academic research and scientific papers

NITRIC OXIDE DONATING DERIVATIVES OF FLUPROSTENOL

The present invention relates to 15-nitrooxyderivatives of fluprostenol, their use for the treatment of glaucoma and ocular hypertension and formulation containing 15-nitrooxy derivatives of fluprostenol.

NITRIC OXIDE DONATING ISOMANNIDE DERIVATIVES

The present invention relates to nitric oxide donating isomannide derivatives, their use for treating glaucoma and ocular hypertension and formulations containing them. The present invention also relates to compositions comprising a nitric oxide donating

NITRIC OXIDE DONATING CARNOSINE COMPOUNDS

The present invention relates to nitric oxide donor carnosine derivatives having a great efficacy in reducing elevated intraocular pressure, to processes for their preparation and to their use in the treatment and/or prophylaxis of glaucoma and ocular hyp

QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS FOR OPHTHALMIC USE

The present invention relates to nitric oxide donor compounds having a quinone based structure of formula (I), wherein R1 to R6, n, m and p are as defined in claim 1, compositions thereof and said compounds for use in the treatment and/or prophylaxis of glaucoma and ocular hypertension.

QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS

The present invention relates to nitric oxide donor compounds having a quinone based structure of formula (I), wherein R1 to R6, m, n and p are as defined in claim 1, to processes for their preparation and to their use in the treatment of pathological conditions where a deficit of NO plays an important role in their pathogenesis, such as pulmonary arterial hypertension, Sickle cell disease, systemic sclerosis and scleroderma, muscular dystrophies, Duchenne's muscular dystrophy and Becker's muscular dystrophy, vascular dysfunctions.

QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS

The present invention relates to nitric oxide donor compounds having a quinone based structure, to processes for their preparation and to their use in the treatment of pathological conditions where a deficit of NO plays an important role in their pathogen

NITRIC OXIDE RELEASING NAPROXEN

The present invention relates to a novel nitric oxide releasing naproxen derivative, its use for the treatment of diseases associated with pain and inflammation. This NO releasing naproxen derivative shows a surprisingly improved gastrointestinal safety a

Palladium-catalyzed silane/siloxane reductions in the one-pot conversion of nitro compounds into their amines, hydroxylamines, amides, sulfonamides, and carbamates

A combination of palladium(II) acetate, aqueous potassium fluoride, and polymethylhydrosiloxane (PMHS) facilitates the room-temperature reduction of aromatic nitro compounds to anilines. These reactions tend to be quick (30 min), high-yielding, and tolerate a range of other functional groups. Replacement of PMHS/KF with triethylsilane allows for the reduction of aliphatic nitro compounds to their corresponding hydroxylamines. Depending on the substrate, both conditions can allow for the in situ conversion of the product amines into amides, sulfonamides, and carbamates. Georg Thieme Verlag Stuttgart.

COMBINATION THERAPY FOR TREATING CYCLOOXYGENASE-2 MEDIATED DISEASES OR CONDITIONS IN PATIENTS AT RISK OF THROMBOTIC CARDIOVASCULAR EVENTS

The invention is directed to a method for treating a cyclooxygenase-2 mediated disease or condition in a mammalian patient at risk of a thrombotic cardiovascular event, wherein the patient is on aspirin therapy to reduce the risk of the thrombotic cardiov

NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS

The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. Formula (I). The invention also encompasses certain pharmaceutical compositions and methods for treating cyclooxygenease-2 mediated diseases comprising the use of compounds of Formula I. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic cardiovascular events.